Clinical Trial

Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients

Study acronym: BIO-CFTR
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2016-11-11; most recent amendment 2024-03-08.
Trial Details
NCT Number NCT02965326
Lead Sponsor Hôpital Necker-Enfants Malades
Collaborators: Association Mucoviscidose-ABCF2, Vaincre la Mucoviscidose
Conditions Cystic Fibrosis
Enrollment 75 participants
Start Date 2016-05
Primary Completion 2026-03 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2024-03-12